Opendata, web and dolomites

PAPRAT SIGNED

PAPRAT (Predictive Algorithm for Pre-Rheumatoid Arthritis Treatment). The new and most efficient multiple biomarkers-based system for an early selection of RA treatment intensity

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 PAPRAT project word cloud

Explore the words cloud of the PAPRAT project. It provides you a very rough idea of what is the project "PAPRAT" about.

efficient    genetic    joints    82    difficult    accurate    complete    treatment    patients    degenerative    platform    spanish    licensing    needing    epigenetic    complications    biological    predictive    markers    poorly    bn    multiple    service    rf       launch    outcome    acpa    total    lack    biosimilars    blood    designed    population    delays    therapy    17    medicine    variables    bone    prognosis    administration    genomic    pain    biomarker    classifying    arthritis    suffering    proper    continued    calculate    45    accuracy    trl6    combines    demographical    market    software    anti    aggressive    globally    paprat    index    clinical    discerning    protein    deformity    optimize    rheumatoid       deterioration    validate    reduce    drivers    dmards    citrullinated    40    prepare    spent    classify    medium    organs    yearly    leave    world    remission    severity    unclassified    3m    unnecessary    grow    disability    once    start    few    algorithm    burden    ageing    economic    genetics    combined    health    antibodies    disease    addressable    critical    ra    prognostics    finished    good    personalized   

Project "PAPRAT" data sheet

The following table provides information about the project.

Coordinator
MAKING GENETICS S.L. 

Organization address
address: PLAZA CEIN 1, POLIGONO MOCHOLI, OFICINA R1.9, NOAIN
city: NOAIN
postcode: 31110
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-09-01   to  2020-02-29

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MAKING GENETICS S.L. ES (NOAIN) coordinator 50˙000.00

Map

 Project objective

Rheumatoid arthritis (RA) affects 1% of world population (17.6 M) and it is a relevant economic burden (€45 Bn spent yearly in Europe). It is a degenerative disease that affects bone health, cause joints’ deformity, impact other organs and cause disability. An early and personalized treatment can greatly improve its outcome, achieve remission and reduce pain, thus an accurate prognosis is critical for its efficient management. However, this is difficult for the lack of good prognosis factors (currently rheumatoid factor-RF or anti-citrullinated protein antibodies-ACPA), which at present are very few, poorly accurate and leave 40% of patients unclassified (suffering health complications due to an unnecessary aggressive treatment or from deterioration due to delays in proper treatment). Making Genetics is a Spanish start-up focused in personalized medicine through genomic approaches. We have designed and developed a prognostics test for RA based on a blood test and the use of our new PAPRAT algorithm, with 82.4% accuracy. PAPRAT is a multiple biomarker-based system capable of classifying pre-rheumatoid arthritis patients, discerning which will need a more aggressive treatment. It combines unique genomic markers (genetic and epigenetic), as well as clinical and demographical variables, to calculate a predictive index and classify patients’ RA severity as HIGH (needing early administration of a combined therapy with biological DMARDs) or LOW and MEDIUM (non-biological DMARDs are enough). It is at a TRL6 and now we aim to optimize it, further validate it, develop a software platform and prepare its market launch. RA is expected to grow by drivers such as an ageing population or the continued uptake of biosimilars, and we have currently a total addressable market of 17.6 M patients globally and of around 3M in Europe. We will offer a complete prognosis service, including the blood testing, as well as the licensing of our software platform once it is finished.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PAPRAT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PAPRAT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DetectInMen (2019)

Infection detection in human semen

Read More  

QTB4AMR (2019)

Utilizing an innovative chemical platform to defeat antimicrobial resistance

Read More  

Savesight (2020)

Contact lens embedded sensor for ocular hypertension and glaucoma monitoring

Read More